Exelixis Share Price Today
(NASDAQ: EXEL)

Name: Exelixis Share Price Today (NASDAQ: EXEL) - Exelixis Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Exelixis share price is $33.15 & ₹2,872.12 as on 1 Feb 2025, 2.30 'hrs' IST

$33.15

▲

0.22

(0.67%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Exelixis share price in Dollar and Rupees. Guide to invest in Exelixis stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Exelixis, along with analyst recommendations, forecasts, and comprehensive financials.

Exelixis share price movements

Today's Low: $32.98
Today's High: $33.65
$33.15
0.53%
Downside
Day's Volatility :2.01%
Upside
1.49%
52 Weeks Low: $20.02
52 Weeks High: $37.59
$33.15
39.62%
Downside
52 Weeks Volatility :46.75%
Upside
11.81%

Exelixis (EXEL) Returns

Period	Exelixis, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-3.97%	0.3%	0.0%
6 Months	40.01%	-1.5%	0.0%
1 Year	53.23%	5.0%	0.0%
3 Years	83.76%	12.3%	-12.8%

Exelixis (EXEL) Key Statistics

in dollars & INR

Previous Close	$32.93
Open	$32.92
Today's High	$33.65
Today's Low	$32.975
Market Capitalization	$9.4B
Today's Volume	$2.1M
52 Week High	$37.59
52 Week Low	$20.015
Revenue TTM	$2.1B
EBITDA	$636.0M
Earnings Per Share (EPS)	$1.55
PE Ratio	21.25
Profit Margin	22.43%
Quarterly Earnings Growth YOY	121.7%
Return On Equity TTM	20.2%

How to invest in Exelixis Stock (EXEL) from India?

It is very easy for Indian residents to invest directly in Exelixis from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Exelixis stock in both Indian Rupees (INR) and US Dollars (USD). Search for Exelixis or EXEL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Exelixis or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Exelixis shares which would translate to 0.026 fractional shares of Exelixis as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Exelixis, in just a few clicks!

Returns in Exelixis (EXEL) for Indian investors in Rupees

The Exelixis stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Exelixis investment value today

Current value as on today

₹1,58,677

Returns

₹58,677

(+58.68%)

Returns from Exelixis Stock

₹54,258 (+54.26%)

Dollar Returns

₹4,419 (+4.42%)

Indian investors sentiment towards Exelixis (EXEL)

38%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Exelixis Stock from India on INDmoney has increased by 38% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Exelixis

BlackRock Inc
11.23%
Vanguard Group Inc
10.26%
Farallon Capital Management, L.L.C.
8.90%
Renaissance Technologies Corp
5.38%
State Street Corp
4.01%
LSV Asset Management
2.84%

Analyst Recommendation on Exelixis

Buy

76%Buy

19%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Exelixis(by analysts ranked 0 to 5 stars)

Based on 26 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Exelixis Stock (EXEL)

What analysts predicted

Upside of 8.37%

Target:

$35.93

Current:

$33.15

Insights on Exelixis Stock (Ticker Symbol: EXEL)

Price Movement
In the last 6 months, EXEL stock has moved up by 40.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 637.17M → 539.54M (in $), with an average decrease of 15.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 226.11M → 117.97M (in $), with an average decrease of 47.8% per quarter
EXEL vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.3% return, outperforming this stock by 9.0%
EXEL vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 101.4% return, outperforming this stock by 19.5%
Price to Sales
ForEXEL every $1 of sales, investors are willing to pay $4.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.8 for every $1 of sales.

EXEL Exelixis Financials in INR & Dollars

	FY20	Y/Y Change
Revenue	$987.5M	↑ 2.04%
Net Income	$111.8M	↓ 65.18%
Net Profit Margin	11.32%	↓ 21.85%

	FY21	Y/Y Change
Revenue	$1.4B	↑ 45.31%
Net Income	$231.1M	↑ 106.71%
Net Profit Margin	16.1%	↑ 4.78%

	FY21	Y/Y Change
Revenue	$1.4B	↑ 45.31%
Net Income	$231.1M	↑ 106.71%
Net Profit Margin	16.1%	↑ 4.78%

	FY22	Y/Y Change
Revenue	$1.6B	↑ 12.27%
Net Income	$182.3M	↓ 21.11%
Net Profit Margin	11.31%	↓ 4.79%

	FY22	Y/Y Change
Revenue	$1.6B	↑ 12.27%
Net Income	$182.3M	↓ 21.11%
Net Profit Margin	11.31%	↓ 4.79%

	FY23	Y/Y Change
Revenue	$1.8B	↑ 13.6%
Net Income	$207.8M	↑ 13.98%
Net Profit Margin	11.35%	↑ 0.04%

	Q2 FY23	Q/Q Change
Revenue	$469.8M	↑ 14.94%
Net Income	$81.2M	↑ 102.8%
Net Profit Margin	17.28%	↑ 7.49%

	Q3 FY23	Q/Q Change
Revenue	$471.9M	↑ 0.44%
Net Income	$1.0M	↓ 98.72%
Net Profit Margin	0.22%	↓ 17.06%

	Q4 FY23	Q/Q Change
Revenue	$479.7M	↑ 1.64%
Net Income	$85.5M	↑ 8114.99%
Net Profit Margin	17.83%	↑ 17.61%

	Q1 FY24	Q/Q Change
Revenue	$425.2M	↓ 11.35%
Net Income	$37.3M	↓ 56.36%
Net Profit Margin	8.78%	↓ 9.05%

	Q2 FY24	Q/Q Change
Revenue	$637.2M	↑ 49.84%
Net Income	$226.1M	↑ 505.93%
Net Profit Margin	35.49%	↑ 26.71%

	Q3 FY24	Q/Q Change
Revenue	$539.5M	↓ 15.32%
Net Income	$118.0M	↓ 47.83%
Net Profit Margin	21.87%	↓ 13.62%

	FY20	Y/Y Change
Profit	$951.3M	-

	FY21	Y/Y Change
Profit	$1.4B	-

	FY22	Y/Y Change
Profit	$1.6B	-

	FY23	Y/Y Change
Profit	$1.8B	↑ 13.17%

	Q2 FY23	Q/Q Change
Profit	$452.1M	↑ 14.62%

	Q3 FY23	Q/Q Change
Profit	$453.1M	↑ 0.22%

	Q4 FY23	Q/Q Change
Profit	$457.9M	↑ 1.05%

	Q1 FY24	Q/Q Change
Profit	$404.0M	↓ 11.78%

	Q2 FY24	Q/Q Change
Profit	$619.5M	↑ 53.36%

	Q3 FY24	Q/Q Change
Profit	$522.2M	↓ 15.71%

	FY18	Y/Y Change
Operating Cash Flow	$415.7M	↑ 151.02%
Investing Cash Flow	$-297.9M	↓ 909.48%
Financing Cash Flow	$9.7M	↓ 105.7%

	FY19	Y/Y Change
Operating Cash Flow	$527.0M	↑ 26.76%
Investing Cash Flow	$-587.2M	↑ 97.16%
Financing Cash Flow	$12.6M	↑ 29.53%

	FY20	Y/Y Change
Operating Cash Flow	$209.0M	↓ 60.34%
Investing Cash Flow	$-131.2M	↓ 77.66%
Financing Cash Flow	$-25.1M	↓ 300.21%

	FY21	Y/Y Change
Operating Cash Flow	$400.8M	↑ 91.79%
Investing Cash Flow	$-42.9M	↓ 67.32%
Financing Cash Flow	$-14.8M	↓ 41.11%

	FY22	Y/Y Change
Operating Cash Flow	$362.6M	↓ 9.53%
Investing Cash Flow	$-524.4M	↑ 1122.87%
Financing Cash Flow	$586.0K	↓ 103.96%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$121.0M	↑ 43.33%
Investing Cash Flow	$-73.8M	↑ 48.78%
Financing Cash Flow	$-124.8M	↓ 2821.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$117.4M	↓ 2.98%
Investing Cash Flow	$34.7M	↓ 147.01%
Financing Cash Flow	$-219.7M	↑ 76.03%

Exelixis Technicals Summary

Sell

Neutral

Buy

Exelixis is currently in a neutral trading position according to technical analysis indicators.

Exelixis (EXEL) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Exelixis, Inc.	-2.98%	40.01%	53.23%	83.76%	88.39%
Biontech Se	4.84%	54.26%	30.47%	-32.9%	299.34%
Regeneron Pharmaceuticals, Inc.	-4.49%	-36.24%	-27.73%	9.67%	100.25%
Vertex Pharmaceuticals Incorporated	8.04%	-8.07%	3.23%	72.89%	90.19%
Alnylam Pharmaceuticals, Inc.	18.64%	4.59%	60.15%	90.8%	141.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Exelixis, Inc.	21.25	21.25	2.27	1.94	0.2	0.13	NA	7.96
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.01	17.01	1.06	45.08	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.16	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Exelixis, Inc.	Buy	$9.4B	88.39%	21.25	22.43%
Biontech Se	Buy	$29.0B	299.34%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.5B	100.25%	17.01	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$113.7B	90.19%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.3B	141.72%	NA	-15.86%

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Organization	Exelixis
Employees	1310
CEO	Dr. Stelios Papadopoulos Ph.D.
Industry	Health Technology

Management People of Exelixis

Name	Title
Dr. Stelios Papadopoulos Ph.D.	Co-Founder & Chair of the Board
Dr. Michael M. Morrissey Ph.D.	CEO, President & Director
Mr. Christopher J. Senner	Executive VP & CFO
Dr. Dana T. Aftab Ph.D.	Executive VP of Discovery and Translational Research & Chief Scientific Officer
Mr. Jeffrey J. Hessekiel J.D.	Executive VP & General Counsel
Dr. Amy C. Peterson M.D.	Executive VP, Product Development & Medical Affairs and Chief Medical Officer
Ms. Susan T. Hubbard	Executive Vice President of Public Affairs & Investor Relations
Mr. Tony Redmond	Senior Vice President of Human Resources
Dr. Anne Champsaur M.D.	Senior Vice President of Drug Safety
Dr. William Berg M.D.	Senior Vice President of Medical Affairs

Important FAQs about investing in EXEL Stock from India :

What is Exelixis share price today?

Exelixis share price today stands at $33.15, Open: $32.92 ; Previous Close: $32.93 ; High: $33.65 ; Low: $32.98 ; 52 Week High: $37.59 ; 52 Week Low: $20.02.

The stock opens at $32.92, after a previous close of $32.93. The stock reached a daily high of $33.65 and a low of $32.98, with a 52-week high of $37.59 and a 52-week low of $20.02.

Can Indians buy Exelixis shares?

Yes, Indians can invest in the Exelixis (EXEL) from India.

With INDmoney, you can buy Exelixis at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Exelixis at zero transaction cost.

How can I buy Exelixis shares from India?

It is very easy to buy Exelixis from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Exelixis (EXEL) be purchased?

Yes, you can buy fractional shares of Exelixis with INDmoney app.

What are the documents required to start investing in Exelixis stocks?

To start investing in Exelixis, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.